Fate Therapeutics Share Price (NASDAQ: FATE)

$1.04

▲

-0.04

(-3.7%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Fate Therapeutics Stock chart to analyse performance

Fate Therapeutics stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$1.04
Today's High:$1.09
$1.04
0.48%
Downside
Day's Volatility :5.05%
Upside
4.59%
52 Weeks Low:$0.66
52 Weeks High:$4.20
$1.04
36.44%
Downside
52 Weeks Volatility :84.26%
Upside
75.24%

Fate Therapeutics Stock Returns

Period	Fate Therapeutics Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-19.62%	3.6%	0.0%
6 Months	1.46%	-7.7%	0.0%
1 Year	-69.71%	-12.6%	0.0%
3 Years	-96.13%	9.5%	-4.7%

Fate Therapeutics Inc Key Stats

Check Fate Therapeutics key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$1.08
Open	$1.095
Today's High	$1.09
Today's Low	$1.035
Market Capitalization	$119.9M
Today's Volume	$893.4K
52 Week High	$4.2
52 Week Low	$0.66105
Revenue TTM	$8.5M
EBITDA	$-161.6M
Earnings Per Share (EPS)	$-1.46
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-52.11%

Stock Returns calculator for Fate Therapeutics Stock including INR - Dollar returns

The Fate Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Fate Therapeutics investment value today

Current value as on today

₹35,429

Returns

₹64,571

(-64.57%)

Returns from Fate Therapeutics Stock

₹69,855 (-69.86%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Fate Therapeutics Stock

106%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Fate Therapeutics Stock from India on INDmoney has increased by 106% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Fate Therapeutics Inc

Name
Holdings %
Name
Holdings %
Redmile Group, LLC
11.23%
BlackRock Inc
9.32%
Vanguard Group Inc
7.65%
Citadel Advisors Llc
3.74%
JPMorgan Chase & Co
2.96%
Johnson & Johnson
2.95%

Analyst Recommendation on Fate Therapeutics Stock

Rating

Trend

Hold

42%Buy

53%Hold

3%Sell

Based on 26 Wall street analysts offering stock ratings for Fate Therapeutics(by analysts ranked 0 to 5 stars)

Fate Therapeutics Share Price Target

What analysts predicted

Upside of 375.96%

Target:

$4.95

Current:

$1.04

Fate Therapeutics share price target is $4.95, a slight Upside of 375.96% compared to current price of $1.04 as per analysts' prediction.

Fate Therapeutics Stock Insights

Price Movement
In the last 7 days, FATE stock has moved down by -9.1%
Increasing Revenue
Revenue is up for the last 2 quarters, 1.62M → 1.90M (in $), with an average increase of 14.6% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -52.15M → -34.07M (in $), with an average increase of 24.5% per quarter
FATE vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.9% return, outperforming this stock by 141.4%
FATE vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 112.6% return, outperforming this stock by 208.6%
Price to Sales
ForFATE every $1 of sales, investors are willing to pay $14.5, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.5 for every $1 of sales.

Fate Therapeutics Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$10.7M	↑ 125.32%
Net Income	$-97.7M	↑ 46.71%
Net Profit Margin	-914.87%	↑ 490.15%

	FY20	Y/Y Change
Revenue	$31.4M	↑ 194.33%
Net Income	$-173.4M	↑ 77.45%
Net Profit Margin	-551.59%	↑ 363.28%

	FY21	Y/Y Change
Revenue	$55.8M	↑ 77.66%
Net Income	$-212.2M	↑ 22.36%
Net Profit Margin	-379.89%	↑ 171.7%

	FY22	Y/Y Change
Revenue	$96.3M	↑ 72.44%
Net Income	$-255.1M	↑ 20.22%
Net Profit Margin	-264.86%	↑ 115.03%

	FY23	Y/Y Change
Revenue	$63.5M	↓ 34.03%
Net Income	$-160.9M	↓ 36.9%
Net Profit Margin	-253.3%	↑ 11.56%

	FY24	Y/Y Change
Revenue	$13.6M	↓ 78.55%
Net Income	$-186.3M	↑ 15.74%
Net Profit Margin	-1.4K%	↓ 1113.16%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$1.9M	↑ 14.86%
Net Income	$-48.0M	↑ 8.8%
Net Profit Margin	-2.5K%	↑ 138.87%

	Q2 FY24	Q/Q Change
Revenue	$6.8M	↑ 251.79%
Net Income	$-38.4M	↓ 19.95%
Net Profit Margin	-567.44%	↑ 1926.27%

	Q3 FY24	Q/Q Change
Revenue	$3.1M	↓ 54.61%
Net Income	$-47.7M	↑ 24.07%
Net Profit Margin	-1.6K%	↓ 983.57%

	Q4 FY24	Q/Q Change
Revenue	$1.9M	↓ 39.49%
Net Income	$-52.2M	↑ 9.39%
Net Profit Margin	-2.8K%	↓ 1252.91%

	Q1 FY25	Q/Q Change
Revenue	$1.6M	↓ 12.42%
Net Income	$-37.6M	↓ 27.86%
Net Profit Margin	-2.3K%	↑ 494.47%

	Q2 FY25	Q/Q Change
Revenue	$1.9M	↑ 17.07%
Net Income	$-34.1M	↓ 9.44%
Net Profit Margin	-1.8K%	↑ 522.87%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$-77.1M	↑ 50.32%

	FY20	Y/Y Change
Profit	$-94.2M	↑ 22.18%

	FY21	Y/Y Change
Profit	$50.0M	↓ 153.08%

	FY22	Y/Y Change
Profit	$96.3M	↑ 92.62%

	FY23	Y/Y Change
Profit	$-93.7M	↓ 197.25%

	FY24	Y/Y Change
Profit	$13.6M	↓ 114.55%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$-2.9M	↓ 9.75%

	Q2 FY24	Q/Q Change
Profit	$2.1M	↓ 170.82%

	Q3 FY24	Q/Q Change
Profit	$3.1M	↑ 49.88%

	Q4 FY24	Q/Q Change
Profit	$1.9M	↓ 39.49%

	Q1 FY25	Q/Q Change
Profit	$1.6M	↓ 12.42%

	Q2 FY25	Q/Q Change
Profit	$-1.4M	↓ 184.16%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-83.2M	↑ 115.2%
Investing Cash Flow	$-157.5M	↑ 33907.13%
Financing Cash Flow	$149.9M	↑ 6.5%

	FY20	Y/Y Change
Operating Cash Flow	$-39.2M	↓ 52.84%
Investing Cash Flow	$-161.1M	↑ 2.3%
Financing Cash Flow	$282.8M	↑ 88.65%

	FY21	Y/Y Change
Operating Cash Flow	$-162.9M	↑ 315.18%
Investing Cash Flow	$-324.0M	↑ 101.16%
Financing Cash Flow	$453.1M	↑ 60.21%

	FY22	Y/Y Change
Operating Cash Flow	$-248.2M	↑ 52.4%
Investing Cash Flow	$166.8M	↓ 151.46%
Financing Cash Flow	$9.2M	↓ 97.97%

	FY23	Y/Y Change
Operating Cash Flow	$-132.3M	↓ 46.71%
Investing Cash Flow	$112.7M	↓ 32.44%
Financing Cash Flow	$85.0K	↓ 99.08%

	FY24	Y/Y Change
Operating Cash Flow	$-122.9M	↓ 7.1%
Investing Cash Flow	$12.2M	↓ 89.16%
Financing Cash Flow	$99.9M	↑ 117420.0%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-33.4M	↓ 8.97%
Investing Cash Flow	$17.3M	↓ 61.82%
Financing Cash Flow	$95.5M	↓ 53148.89%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-32.3M	↓ 3.13%
Investing Cash Flow	$-53.4M	↓ 408.26%
Financing Cash Flow	$1.3M	↓ 98.67%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-29.4M	↓ 8.94%
Investing Cash Flow	$25.5M	↓ 147.7%
Financing Cash Flow	$0.0	↓ 100.0%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-27.8M	↓ 5.51%
Investing Cash Flow	$22.8M	↓ 10.39%
Financing Cash Flow	$3.1M	-

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-33.8M	↑ 21.62%
Investing Cash Flow	$42.7M	↑ 87.03%
Financing Cash Flow	$0.0	↓ 100.0%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-24.6M	↓ 27.28%
Investing Cash Flow	$19.6M	↓ 54.09%
Financing Cash Flow	$1.3M	-

Fate Therapeutics Technicals Summary

Sell

Neutral

Buy

Fate Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Fate Therapeutics Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Fate Therapeutics Inc	-2.34%	1.46%	-69.71%	-96.13%	-97.07%
Regeneron Pharmaceuticals, Inc.	6.48%	-15.2%	-50.31%	-3.3%	-2.01%
Beone Medicines Ltd	1.77%	24.81%	62.78%	79.11%	29.69%
Vertex Pharmaceuticals Incorporated	-14.45%	-19.13%	-17.84%	34.68%	41.87%
Alnylam Pharmaceuticals, Inc.	13.79%	83.28%	75.87%	111.28%	242.25%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Fate Therapeutics Inc	NA	NA	0.0	-1.08	-0.52	-0.25	NA	2.28
Regeneron Pharmaceuticals, Inc.	14.6	14.6	1.2	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.73	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.86	27.86	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Fate Therapeutics Inc	Hold	$119.9M	-97.07%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$61.4B	-2.01%	14.6	31.37%
Beone Medicines Ltd	NA	$36.5B	29.69%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.5B	41.87%	27.86	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$59.5B	242.25%	NA	-12.96%

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Organization	Fate Therapeutics
Employees	181
CEO	Dr. Bahram Valamehr M.B.A., Ph.D.
Industry	Health Technology

Key Management of Fate Therapeutics Inc

Name	Title
Dr. Bahram Valamehr M.B.A., Ph.D.	President, CEO & Director
Ms. Cindy R. Tahl J.D.	Chief Legal & Compliance Officer and Corporate Secretary
Mr. Victor Hong	Vice President of Corporate Development & Finance
Ms. Jessica Francis	Vice President Of Human Resources & Operations
Mr. Andrew Henry	Senior Vice President of Clinical Operations
Dr. Tunde Babalola	Senior Vice President of Technical Operations
Dr. Yu Cai	Head of Intellectual Property & Assistant General Counsel
Ms. Kate Duvall	Corporate Controller

Important FAQs about investing in FATE Stock from India :

What is Fate Therapeutics share price today?

Fate Therapeutics share price today is $1.04 as on August 30, 2025 at 1:29 am IST at the close of the market. Fate Therapeutics share today touched a day high of $1.09 and a low of $1.04.

What is the 52 week high and 52 week low for Fate Therapeutics share?

Fate Therapeutics share touched a 52 week high of $4.20 and a 52 week low of $0.66. Fate Therapeutics stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $1.04, lower by 75.24% versus the 52 week high.

How to invest in Fate Therapeutics Stock (FATE) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Fate Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Fate Therapeutics Shares that will get you 1.4423 shares as per Fate Therapeutics share price of $1.04 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Fate Therapeutics Stock (FATE) from India?

Indian investors can start investing in Fate Therapeutics (FATE) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Fate Therapeutics stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Fate Therapeutics share’s latest price of $1.04 as on August 30, 2025 at 1:29 am IST, you will get 9.6154 shares of Fate Therapeutics. Learn more about fractional shares .

What are the returns that Fate Therapeutics has given to Indian investors in the last 5 years?

Fate Therapeutics stock has given -97.07% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?